Industry News AstraZeneca / Alexion BioPharma Dive

AstraZeneca's Klygefa approved as a self-administered C5 option in myasthenia gravis

  • FDA approved gefurulimab, to be sold as Klygefa, for generalized myasthenia gravis.
  • It is a C5 inhibitor that AstraZeneca gained through its Alexion acquisition.
  • Positioned as self-administered, in contrast to Alexion's infused Soliris and Ultomiris.
Points Based on public reports

The strategic point is cannibalization management: AstraZeneca is launching a self-injected C5 inhibitor against its own infused franchise, which only makes sense as a defense against FcRn and generic eculizumab pressure. Convenience is the pitch, so pricing relative to Ultomiris and uptake among patients already on infusions are the numbers to watch; the roundup gives no efficacy or price detail, so neither can be judged yet.